AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Eli Lilly Partners with JD Health for Direct-to-Consumer Obesity and Diabetes Drug Sales
ByAinvest
Friday, Aug 29, 2025 5:42 am ET1min read
Eli Lilly is partnering with JD Health International to sell its obesity and diabetes drugs online in China. The partnership will provide a one-stop service for consultations, prescriptions, and drug delivery through JD Health's platform. This move follows competitors Novo Nordisk in leveraging e-commerce channels to drive sales in the GLP-1 drug market, which is expected to grow to $5.6-$11.4 billion annually.
Eli Lilly & Co. has announced a strategic partnership with JD Health International Inc., a prominent Chinese online healthcare platform, to sell its blockbuster obesity and diabetes drugs online. This move follows a trend of pharmaceutical companies leveraging e-commerce channels to drive sales in the growing GLP-1 drug market in China [1].The partnership will facilitate a one-stop service for consultations, prescriptions, and drug delivery through JD Health's platform. This initiative aims to ease access to Lilly's drugs, including Mounjaro, which is marketed for both obesity and diabetes in China. The decision to prioritize online retail channels is a response to China's state medical insurance policy, which does not cover weight loss drugs, prompting drugmakers to shift towards retail and online sales [1].
This partnership is a significant step for Eli Lilly, which has been following the lead of competitors like Novo Nordisk in exploring direct-to-consumer sales. Novo Nordisk has already struck similar deals with various online health platforms, including JD Health, Tencent Health, and Alibaba Health Information Technology Ltd. [1].
The GLP-1 drug market in China is expected to grow to between $5.6 billion and $11.4 billion annually, making it a crucial battlefield for pharmaceutical companies. Eli Lilly's move to capitalize on this growing market underscores the company's strategic focus on expanding its reach in the lucrative Chinese market [1].
The partnership with JD Health International is part of Eli Lilly's broader strategy to enhance its market presence in China. By providing a seamless online service, Lilly aims to improve patient access to its medications and potentially increase market share in the competitive GLP-1 drug market.
References:
[1] https://www.bloomberg.com/news/articles/2025-08-29/eli-lilly-partners-with-china-tech-giant-for-obesity-drug-sales
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet